Aldeyra Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $11.4M | $59.5M | $77.9M |
| FY2021 | $15.5M | $205.7M | $229.8M |
| FY2022 | $14.9M | $151.0M | $144.4M |
| FY2023 | $0 | $119.8M | $142.8M |
| FY2024 | $15.0M | $71.0M | $54.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $11.4M | $59.5M | $77.9M |
| FY2021 | $15.5M | $205.7M | $229.8M |
| FY2022 | $14.9M | $151.0M | $144.4M |
| FY2023 | $0 | $119.8M | $142.8M |
| FY2024 | $15.0M | $71.0M | $54.5M |